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Abstract Misoprostol is reported to prevent non-steroidal
anti-inflammatory drug (NSAID)-associated gastroduode-
nal complications. There is, however, limited information
regarding the efficacy of DA-9601 in this context. We
performed a comparative study on the relative efficacy of
DA-9601 and misoprostol for prevention of NSAID-asso-
ciated complications. In this multicenter, double-blinded,
active-controlled, stratified randomized, parallel group,
non-inferiority trial, 520 patients who were to be treated
with an NSAID (aceclofenac, 100 mg, twice daily) over a
4-week period were randomly assigned to groups for
coincidental treatment with DA-9601 (60 mg, thrice daily)
(236 patients for full analysis) or misoprostol (200 lg,
thrice daily) (242 patients for full analysis). A total of 236
patients received DA-9601 and 242 received misoprostol.
The primary endpoint was the gastric protection rate, and
secondary endpoints were the duodenal protection rate and
ulcer incidence rate. Endpoints were assessed by endos-
copy after the 4-week treatment period. Drug-related
adverse effects, including gastrointestinal (GI) symptoms,
were also compared. At week 4, the gastric protection rates
with DA-9601 and misoprostol were 81.4 % (192/236) and
89.3 % (216/242), respectively. The difference between the
groups was -14.2 %, indicating non-inferiority of DA-
9601 to misoprostol. Adverse event rates were not different
between the two groups; however, the total scores for GI
symptoms before and after administration were signifi-
cantly lower in the DA-9601 group than in the misoprostol
group (-0.2 ± 2.8 vs 1.2 ± 3.2; p \ 0.0001). DA-9601 is
as effective as misoprostol in preventing NSAID-
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associated gastroduodenal complications, and has a supe-
rior adverse GI effect profile.
Keywords DA-9601(Stilen)  Misoprostol  NSAID-
associated  Gastroduodenal injury
Introduction
Despite the various gastroduodenal complications associ-
ated with non-steroidal anti-inflammatory drugs (NSAIDs),
they remain a desirable treatment for patients with mus-
culoskeletal pain or other inflammatory conditions.
NSAID-associated gastroduodenal complications include
mild forms of gastropathy such as erosive gastritis and
dyspepsia, in addition to more serious gastric or duodenal
ulcers. Moreover, life-threatening gastrointestinal (GI)
bleeding may be caused by chronic NSAID use (Garcı´a
Rodrı´guez and Jick 1994). These NSAID-associated gas-
troduodenal complications are attributable to the depletion
of prostaglandin in the gastroduodenal mucosa, by inhibi-
tion of cyclooxygenase (COX), which is known to play an
essential role in maintaining mucosal integrity (Schoen and
Vender 1989). Replenishment of prostaglandin with
misoprostol has, therefore, been used to prevent NSAID-
associated gastroduodenal complications (Silverstein et al.
1995). In comparison with a placebo, misoprostol was
shown to significantly reduce the incidence of gastroduo-
denal ulcers in chronic NSAID users (Graham et al. 2002;
Hawkey et al. 1998).
Because NSAID-associated gastroduodenal injury can
be facilitated by low intragastric pH, antisecretory agents
such as H2 receptor antagonists (H2RAs) and proton pump
inhibitors (PPIs) are commonly prescribed to reduce the
risk of NSAID-associated gastroduodenal injury in patients
being treated with NSAIDs (Agrawal et al. 2000).
Administration of antisecretory agents is recommended for
chronic NSAID users (Weaver and Gitlin 2002). When
compared with PPIs, misoprostol has been demonstrated to
be efficacious in preventing NSAID-associated gastroduo-
denal complications. Administration of misoprostol is
associated with side effects including diarrhea, nausea, and
abdominal pain. Studies comparing misoprostol with a
H2RA or PPI have reported lower compliance in the case of
misoprostol, preventing accurate assessment of drug
efficacy.
In addition to COX inhibition and resultant prostaglan-
din depletion, NSAIDs may cause leukocyte recruitment
and generation of reactive oxygen species (ROS), which
may contribute towards gastroduodenal injury (Hussain
et al. 2012). Inhibiting the development of ROS using
antioxidants, such as DA-9601, may therefore represent a
different modality for prevention of NSAID-associated GI
complications. DA-9601 (Stillen) is a phytopharmaceutical
derived from Artemisia asiatica, which has antioxidative
and anti-inflammatory actions in the context of experi-
mentally induced GI mucosal damage (Kim et al. 2004). In
former double-blinded cetraxate-controlled phase III clin-
ical studies, administration of DA-9601 was effective for
treatment of erosive gastritis of various etiologies, and was
well tolerated.
In a previous report, the preventive effect of DA-9601
and misoprostol on NSAID-associated gastroduodenal
injury was established in healthy volunteers using a ran-
domized, double-blinded, multicenter study. DA-9601 was
shown to not be inferior to misoprostol in terms of endo-
scopic gastroduodenal protection rates. The study also
indicated that the side-effect profile of DA-9601 was
superior to that of misoprostol (Lee et al. 2011). However,
compared with healthy volunteers, patients with arthritis
are more susceptible to developing NSAID-associated
gastropathies (McCafferty et al. 1995; Kato and Takeuchi
2002). Furthermore, the risk of development of a serious
NSAID-associated peptic ulcer is increased in the elderly
(Griffin et al. 1988, 1991; Hong et al. 2013).
We, therefore, conducted a multicenter, double-blinded,
stratified randomized, active-controlled, parallel group,
non-inferiority study to investigate whether DA-9601 is
comparable to misoprostol in reducing NSAID-associated
gastroduodenal complications. Both drug efficacy and
safety were assessed.
Table 1 Endoscopic scoring of gastric mucosal lesions
Score Gastric mucosal lesion status
0 No visible lesions
1 Mucosal hemorrhages only
2 1 or 2 erosions
3 Numerous (3–10) areas of erosions
4 Large number ([10) of erosions
5 Ulcer
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Eligible patients were 20–65 years of age, on a course of
NSAIDs for more than 4 weeks, experiencing pain due to
rheumatoid arthritis, ankylosing spondylitis, osteoarthritis,
frozen shoulders, toothache, trauma-associated inflamma-
tion, lumbar pain, ischialgia, or nonarthritic rheumatism,
and had normal baseline endoscopic findings with no ero-
sion or ulcer (i.e., grading scores of 0–1 based on gastric
mucosal lesions, irrespectively of duodenal mucosal
lesions) (Table 1).
Exclusion criteria were a history of gastric or duodenal
ulcer within the previous 30 days, previous GI surgery, a
history of hypersensitivity to any drug, drug dependency,
any use of histamine 2 receptor antagonists, PPIs, sucral-
fate, misoprostol, DA-9601, triamterene, corticosteroids,
cyclophosphamide, methotrexate, or NSAIDs (except for
acetaminophen or aspirin not exceeding 200 mg/d) within
7 days of randomization. Pregnant or lactating females,
and females of childbearing age not using contraception,
were excluded. Patients were also excluded if they had
major hematologic, renal, cardiac, pulmonary, and hepatic
abnormalities, thrombotic disorders, consumption coagu-
lopathy, acute hepatitis, pancreatitis, inflammatory bowel
disease, or psychiatric disorders. Those with hypersensi-
tivity to prostaglandin, aceclofenac, or drugs of the same
class as aceclofenac, were also excluded.
Study design
This study was a multicenter, double-blinded, stratified
randomized, active-controlled, parallel group, non-inferi-
ority trial conducted in South Korea from September 2012
to March 2014. Patients meeting the study criteria under-
went a screening endoscopy within 1 week of the screening
period, or, for those already taking an NSAID, after a run-
in period of at least 1 week. During the washout period of
1 week, acetaminophen (Tylenol) was permitted as a res-
cue drug. Following the 1-week screening period, eligible
patients were randomly assigned to either the DA-9601
(60 mg; Stillen; Dong-A ST Co., Seoul, Korea) or miso-
prostol (100 lg; Cytotec; Pfizer Pharmaceuticals Korea)
treatment groups. DA-9601 and misoprostol were taken
three times daily for 4 weeks, concurrent with twice-daily
treatment with an NSAID (aceclofenac, 100 mg). Treat-
ment assignments were carried out by a computer-gener-
ated randomization program that was designed to allocate
patients to the two treatment groups in a 1:1 ratio. The
subjects were assigned sequential allocation numbers at
each site, and the medications were presented as two
identical-appearing tablets containing an active drug or a
placebo, in order to maintain the double blind condition.




Each subject underwent an upper GI endoscopy to establish
a baseline, and again after the 4-week treatment period.
The primary endpoint was the gastric mucosa protection
rate at week 4, based on endoscopy scores ranging from 0
to 5 (0, no visible lesion; 1, mucosal hemorrhage only; 2,
one or two erosions; 3, three to ten erosions; 4, more than
10 erosions; 5, ulcer) (Table 1). The protection rate was the
percentage of patients who were shown to be protected at
follow-up endoscopy (defined as endoscopy scores of 0–1)
after 4 weeks of treatment. Secondary endpoints were the
duodenal mucosa protection rate and the ulcer incidence
rate at week 4. Drug compliance was assessed every day
using a telephone-based interactive voice response system
to ask patients whether they had taken the prescribed
medications.
Safety
The incidence of adverse events, including any GI symp-
toms, and abnormalities in laboratory findings and vital
signs, was assessed. GI symptoms consisted of abdominal
pain, diarrhea, heartburn, nausea, vomiting, bloating,
anorexia, and constipation.
Ethics statement
The study was approved by the Institutional Review Board
of each of the 36 participating institutions, including Inje
University Busan Paik Hospital (IRB approval number:
11-183), The Catholic University of Korea Seoul St.
Mary’s Hospital (KC11MSMV0970), Seoul National
University Hospital of Bundang (B-1206-160-001), Sev-
erance Hospital Yonsei University (4-2012-0324), Won-
kwang University Hospital (1368), Chonnam National
University Hospital (CNUH-2012-004), The Catholic
University of Korea St.Vincent’s Hospital (VC12MSMV
0100), KyungHee University Medical Center (1217-04),
Korea University Anam Hospital (AN12069-001), Korea
University Ansan Hospital (AS12049), Kosin University
Gospel Hospital (07), Daegu Catholic University Medical
Center (CR-12-070), Pusan National University Hospital
(H-1205-005-006), Kyungpook National University Hos-
pital (KNUH 2013-01-036), Soonchunhyang University
Hospital Cheonan (13), Chonbuk National University
Hospital (CUH 2011-12-008-002), Chung-Ang University
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Hospital (C2012072(767)), Samsung Medical Center
(SMC 2012-05-074), Kyungpook National University
Hospital (KNUMC_12-0009), Ajou University Medical
Center (AJIRB-MED-CT4-12-149), Gangnam Severance
Hospital Yonsei University (15), Youngnam University
Medical Center (YUH-12-0383-M26), Inha University
Hospital (12-104), Hanyang University Medical Center
(HYUH 2011-11-005), Hanyang University Guri Hospital
(2012-029), Gachon University Gil medical Center
(GBIRB2013-246), The Catholic University of Korea
Yeouido St. Mary’s Hospital (SC13MSMV0158), Kangbuk
Samsung Medical Center (KBC13168), Gyeongsang
National University Hospital (GNUH 2013-09-013), Ke-
imyung University Dongsan Medical Center (2013-08-
004), Pusan Nsational University Yangsan Hospital (02-
2013-023), Wonju Severance Christian Hospital
(CR113029-001), Inje University Haeundae Paik Hospital
(129792-2013-074), Presbyterian Medical Center (2013-
08-31), Jeju National University Hospital (JEJUNUH
2013-07-014) and Dongguk University Ilsan Hospital
(2013-115). The study was performed in compliance with
good clinical practices, according to ICH guidelines.
Statistical analysis
Based on the results of the previous study, the gastric
mucosa protection rate, as assessed by endoscopy, was set
at 86 and 95 % for DA-9601 and misoprostol, respectively.
The non-inferiority margin was defined as 17 %, identical
to that of the previous study (Lee et al. 2011). The number
of subjects was determined assuming a level of one-sided
significance, a, of 0.025 and an 80 % statistical power. The
target sample size was computed as 420 patients in total;
210 patients per group. Considering an average dropout
rate of 10 %, we aimed to recruit a total of 468 patients.
Demographic and baseline characteristics were sum-
marized descriptively for all participating patient subjects.
For inter-group differences, Student’s t test was used to
evaluate the statistical significances of continuous data, and
a Chi squared test was used for categorical data.
All efficacy analyses were performed on the full analysis
set (FAS) and per-protocol set (PPS). The FAS population
included all randomized subjects who received at least one
dose of study drug and had at least one valid post-baseline
efficacy evaluation. The PPS population was defined as a
subset of the FAS population who completed the study
without any major protocol violations.
For the primary efficacy analysis, a one-sided 97.5 %
lower limit of difference rate between the two groups was
computed. The gastric mucosa protection rate of DA-9601
(test group) could be considered non-inferior to miso-
prostol (control group) if the one-sided 97.5 % lower limit
was greater than -17, the non-inferiority margin.
The differences in the duodenal mucosa protection rate
and the ulcer incidence rate between the two groups were
analyzed using Fisher’s exact test.
For adverse events, the number of patients who expe-
rienced one or more adverse drug reactions was recorded.
Data are presented as percentages and two-sided 95 %
confidence intervals (CI). Inter-group comparisons were
conducted using a Chi squared test.
Results
Baseline characteristics
A total of 621 patients were evaluated for screening.
After excluding 101 patients during the screening period,
520 patients were randomly assigned to either the DA-
9601 or the misoprostol treatment group. Nine percent of
patients in the DA-9601 (24/256) and misoprostol (23/
264) groups did not complete the study. Data on the
remaining 478 patients were available for the FAS ana-
lysis: 236 for DA-9601 versus 242 for misoprostol. Data
on 395 patients were available for the PPS analysis: 196
for DA-9601 versus 199 for misoprostol. Figure 1 pre-
sents a flowchart of patient progression through the
study, with the reasons for premature discontinuation.
Baseline characteristics of the patients are presented in
Table 2. There were no differences between the groups
in terms of gender, age, smoking status and alcohol
consumption.
Efficacy
The FAS population contained 478 patients (236 in the
DA-9601 group and 242 in the misoprostol group). The
gastric mucosa protection rates were, 81.4 and 89.3 % in
the DA-9601 and misoprostol groups at week 4, respec-
tively. The one-sided 97.5 % lower limit was -14.2 %,
which is higher than the -17 % margin of non-inferiority,
indicating non-inferiority of DA-9601 to misoprostol
(Table 3).
In secondary efficacy analyses, the duodenal mucosa
protection rate and the ulcer incidence rate were not sig-
nificantly different between the two groups. The duodenal
mucosa protection rates were 98.7 and 98.8 % in the DA-
9601 and misoprostol groups, respectively. The 95 % CI
for the difference between the groups was -2.0 to 2.0
(Table 4). The ulcer incidence rates were 2.1 and 0.8 % in
the DA-9601 and misoprostol groups, respectively. The
95 % CI for the difference between the groups was -0.9 to
3.5 (Table 5).
A comparative study of DA-9601 1311
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Safety
The incidence rate of adverse events (AEs), adverse drug
reactions (ADRs), severe adverse events (SAEs), and severe
adverse drug reactions (SDARs) were not different between
the DA-9601 and misoprostol groups (29.9 vs. 31.9 %
(p = 0.61), 10.4 vs. 14.1 % (p = 0.20), 0.4 vs. 0.8 %
(p = 1.00), and 0 vs. 0.4 % (p = 1.00), respectively). GI
symptoms were more frequently reported in the misoprostol
group than in the DA-9601 group. The mean of the total GI
symptom scores for abdominal pain, diarrhea, heartburn,
bloating, and anorexia from the baseline to week 4 were
lower in the DA-9601 group compared to the mean of the
total scores in the misoprostol group. This indicates that the
GI symptoms were significantly improved in the DA-9601
group. There was a significant difference between two
groups (-0.2 ± 2.8 vs. 1.2 ± 3.2, p \ 0.0001; Table 6).
Discussion
The present study evaluated the efficacy of DA-9601
compared with the synthetic prostaglandin E1 analogue,
misoprostol, in reducing NSAID-associated gastroduodenal
complications. This randomized, controlled trial found that
the gastric mucosa protection rate in patients on a 4-week
NSAID treatment course was not lower when they were
administered DA-9601 versus misoprostol. The adverse
effect profiles with respect to GI symptoms were improved
with DA-9601, compared to misoprostol. These results
indicate the non-inferiority of DA-9601 in efficacy and
safety, compared with misoprostol.
DA-9601 effectively and safely protected patients from
gastric mucosal injury during 4-week NSAID treatment.
Our results showed that the gastric mucosa protection rate
of the DA-9601 group was high (81.4 %) and was not
Fig. 1 Enrolment, randomization, and follow-up








Age(year)1 44.1 ± 12.0 44.6 ± 11.9 44.4 ± 11.9 0.6168a
Gender
Male2 89 (34.8) 111 (42.1) 200 (38.5) 0.0880e
Female2 167 (65.2) 153 (58.0) 320 (61.5)
Height(cm)1 163.3 ± 9.1 164.4 ± 9.2 163.9 ± 9.2 0.1622a
Weight(kg)1 63.9 ± 12.8 63.5 ± 13.2 63.7 ± 13.0 0.7308a
Smoking2 47 (18.4) 56 (21.2) 103 (19.8) 0.4145e
Alcohol2 103 (40.2) 106 (40.2) 209 (40.2) 0.9846e
1 Mean ± SD; 2 n (%), a Student’s t test, e Chi squared test
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inferior to that of the misoprostol group (89.3 %). Fur-
thermore, the duodenal mucosa protection rate and the
ulcer incidence rate during the 4-week NSAID treatment
were not significantly different between the DA-9601 and
misoprostol treatment groups. Previously, a similar com-
parative study in healthy volunteers demonstrated that
DA-9601 has a similar efficacy and a favorable safety
profile, compared with misoprostol, in the context of pro-
tection from NSAID-associated GI complications.
The mechanism of action of DA-9601 in preventing
gastric mucosal injury is likely to involve its antioxidant
and cytoprotective anti-inflammatory effects. Many studies
Table 4 Duodenal mucosa
protection rate
f Fisher’s exact test
DA-9601 Misoprostol p value
n (%)
Full analysis set (FAS)
(n = 236) (n = 242)
Duodenal mucosa protection rate 233 (98.7) 239 (98.8) 1.0000f
95 % two-sided exact CI for protection rate [96.3, 99.7] [96.4, 99.7]
95 % two-sided CI for the difference in protection rate [-2.0, 2.0]
Per protocol set (PPS)
(n = 196) (n = 199)
Duodenal mucosa protection rate 194 (99.0) 196 (98.5) 1.0000f
95 % two-sided exact CI for protection rate [96.5, 99.9] [95.7, 99.7]
95 % two-sided CI for the difference in protection rate [-1.7, 2.7]
Table 3 Gastric mucosa
protection rate
3 CI confidence interval. 4 The
exact 95 % CI for protection
rate using binomial distribution
DA-9601 Misoprostol
n (%)
Full analysis set (FAS)
(n = 236) (n = 242)
Gastric mucosa protection rate 192 (81.4) 216 (89.3)
95 % two-sided exact CI3 for protection rate4 [75.8, 86.1] [84.7, 92.9]
97.5 % one-sided lower limit (C-17) for the
difference in protection rate
-14.2
Per protocol set (PPS)
(n = 196) (n = 199)
Gastric mucosa protection rate 157 (80.1) 179 (89.9)
95 % two-sided exact CI for protection rate [73.8, 85.5] [84.9, 93.8]
97.5 % one-sided lower limit (C-17) for the
difference in protection rate
-16.8
Table 5 Ulcer incidence rate
f Fisher’s exact test
DA-9601 Misoprostol p value
n (%)
Full analysis set (FAS)
(n = 236) (n = 242)
Ulcer incidence rate 5 (2.1) 2 (0.8) 0.2799f
95 % two-sided exact CI for ulcer development rate [0.7, 4.9] [0.1, 3.0]
95 % two-sided CI for the difference in ulcer
development rate
[-0.9, 3.5]
Per protocol set (PPS)
(n = 196) (n = 199)
Ulcer incidence rate 5 (2.6) 2 (1.0) 0.2816f
95 % two-sided exact CI for protection rate [0.8, 5.9] [0.1, 3.9]
95 % two-sided CI for the difference in protection rate [-1.1, 4.2]
A comparative study of DA-9601 1313
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have demonstrated these effects of DA-9601 on gastric
epithelial cells. Eupatilin, a major component of DA-9601,
was shown to inhibit the production of FeSO4-induced
ROS inhibited and reduce oxidative-driven gene expres-
sion, resulting in prevention of H2O2-induced gastric epi-
thelial damage (Choi et al. 2008). In gastric epithelial cells,
DA-9601 also inhibited the production of TNF-a, a pro-
inflammatory cytokine, through modulation of p38 kinase-
and NF-jB-dependent pathways (Choi et al. 2006). Fur-
thermore, DA-9601 has anti-inflammatory and cytopro-
tective effects in pancreatic and hepatic cells, (Hahm et al.
1998; Ryu et al. 1998). Cytoprotective effects of DA-9601
have been reported by several animal and human studies.
DA-9601 significantly improved the histopathology of
oxidative injury-induced reflux esophagitis in rats (Oh et al.
2001), and reduced alcohol-induced hemorrhagic injury to
the gastric mucosa in rats, by inhibiting alcohol-induced
xanthine oxidase (Huh et al. 2003). Moreover, in patients
with erosions of the gastric mucosa, DA-9601 effectively
and safely healed the gastric mucosa, as assessed by
endoscopy (Seol et al. 2004).
Although misoprostol is reported to have greater effi-
cacy than a placebo, and a similar effect to H2RAs or PPIs
in reducing NSAID-associated gastroduodenal ulcers, low
compliance has caused limited use of misoprostol (Weaver
and Gitlin 2002; Graham et al. 2002; Hawkey et al. 1998;
Raskin et al. 1996; Valentini et al. 1995; McCarthy 2001).
Chronic NSAID users may stop taking misoprostol, or
physicians may attempt to increase compliance by pre-
scribing a lower dose, resulting in increased risk of
NSAID-induced gastroduodenal complications. We found
that GI symptoms were significantly lower in the DA-9601
group than in the misoprostol group. As these GI symptoms
may be attributable not only to aceclofenac but to miso-
prostol or DA-9601, it can be speculated that DA-9601 also
has a protective effect on NSAID-induced GI symptoms
compared with misoprostol.
Regarding the safety of DA-9601, the percentage of
patients complaining of any drug-related adverse effects
was similar in both groups. AE, ADR, SAE, and SADR
were 29.9, 10.4, 1, 0 % in the DA-9601 group, and 31.9,
14.1, 0.8, and 0.4 %, in the misoprostol group, respec-
tively. The difference in the sum of digestive symptoms
between before and after the 4-week treatment was sig-
nificant (-0.2 vs. 1.2 with DA-9601 vs. misoprostol,
p \ 0.0001). Specifically, the symptom scores for diarrhea,
heartburn, and bloating between before and after drug
treatment were lower in the DA-9601 group than in the
misoprostol group. These findings indicate that DA-9601 is
more favorable than misoprostol, with respect to drug
compliance.
This study assessed NSAID-associated gastroduodenal
complications by performing upper GI endoscopy in all
participants before and after 4 weeks of treatment. Gas-
troduodenal lesions visualized by endoscopy were objec-
tively categorized into five grades, according to the
severity of mucosal lesions. In those using an NSAID
chronically, GI symptoms such as abdominal pain, heart
burn, bloating and dyspepsia are frequently noted but these
symptoms are unpredictable for gastroduodenal lesions
(Larkai et al. 1987). Furthermore, such symptoms are not
well correlated with gastroduodenal lesions assessed by
endoscopy (Singh and Triadafilopoulos 1999). Although
inter-observer variability in assessing gastroduodenal
mucosal lesions by endoscopy is possible, the double-blind
nature of the study ensured that this method produced data
that may be considered objective evidence.
NSAID-induced gastroduodenal complications are
known to develop more frequently in patients with risk
factors such as steroid or anti-coagulant use, history of a
prior peptic ulcer, or advanced age. In the present study,
patients with a high risk of NSAID-induced gastroduodenal
ulcers were excluded. In these patients, the preferred
method of preventing NSAID-associated gastroduodenal
complications is to administer a selective COX-2 inhibitor
with a PPI, which is a strategy with low cost-benefit
ratio (Targownik et al. 2008). The patients enrolled in our
study were those requiring chronic NSAID use who were
considered to have an average risk of NSAID-induced
complications. Therefore, the present study highlights that
the cost-benefit ratio of DA-9601 is more acceptable in
average-risk patients. Another concern is that one of the
Table 6 Difference of mean total scores for GI symptoms at week 0 and week 4
DA-9601 Misoprostol p value
n, mean ± SD, median, min, max
Week 0 236 1.4 ± 2.5, 0.0, 0.0, 19.0 242 1.1 ± 2.0, 0.0, 0.0, 9.0 0.1126b
Week 4 232 1.2 ± 2.2, 0.0, 0.0, 14.0 240 2.3 ± 3.3, 1.0, 0.0, 22.0
Difference between week 0 and week 4 232 -0.2 ± 2.8, 0.0, -15.0, 14.0 240 1.2 ± 3.2, 0.0, -6.0, 22.0 \0.0001b,
P value 0.1355d \0.0001d,
b Wilcoxon rank-sum test d Wilcoxon singed-rank test  p \ 0.05
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important factors for increasing NSAID-induced ulcer is
Helicobacter pyloric infection. A meta-analysis concludes
that NSAIDs and H. pylori have a synergistic risk for
developing peptic ulcer diseases (Huang et al. 2002) and
eradication of H. pylori reduces ulcer incidence (Tang et al.
2012). As this factor was not evaluated in the present study
participants, this may be another limitation to our study.
However, conflicting results also reported that no beneficial
effects of H. pylori eradication was obtained for chronic
NSAID treatment (de Leest et al. 2007).
In summary, the results of this study indicate that DA-
9601 is as effective as misoprostol in protecting against
gastroduodenal injury during a 4-week NSAID treatment
course. Furthermore, DA-9601 was not inferior to miso-
prostol in terms of the adverse effect profile. Some of the
GI symptoms reported during the study were less frequent
in the DA-9601 group than the misoprostol group. There-
fore, to prevent NSAID-associated GI complications, we
recommend administration of DA-9601 (60 mg, three
times per day), rather than misoprostol.
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